Safety and immunogenicity profiles of an adjuvanted seasonal influenza vaccine in Guatemalan children

Journal of Infection in Developing Countries

Volumn 8, Issue 9, 2014, Pages 1160-1168

  Solares, Adib Rodriguez ^a,b   Aragon, Carlos Grazioso ^c   Pivaral, Rodolfo Urruela ^d   Prado Cohrs, David ^e   Groth, Nicola ^f   Pellegrini, Michele ^f   Sales Carmona, Victor ^f  

^a Hospital Infantil de Infectologia Y Rehabilitacion   (Guatemala)

^b Grupo Pediatrico   (Guatemala)

^c Centro de Investigaciones Pediátricas   (Guatemala)

^d Clinica De Ninos   (Guatemala)

^e Fundación Pediátrica Guatemalteca   (Guatemala)

^f Novartis Vaccines and Diagnostics Inc   (United States)

Author keywords

Influenza; MF59; Pediatric; Seasonal; Trivalent; Vaccine

Indexed keywords

INFLUENZA VACCINE; MIFAMURTIDE; TRIPLE VACCINE; IMMUNOLOGICAL ADJUVANT; MF59 OIL EMULSION; POLYSORBATE; SQUALENE; VIRUS ANTIBODY;

ANTIBODY RESPONSE; ANTIBODY TITER; ARTHRALGIA; ARTICLE; CHILD; CHILL; CONTROLLED STUDY; CROSS REACTION; DIARRHEA; DRUG TOLERABILITY; ECCHYMOSIS; ERYTHEMA; FATIGUE; FEMALE; FEVER; GUATEMALAN; HEADACHE; HEMAGGLUTINATION INHIBITION TEST; HUMAN; IMMUNOGENICITY; IMMUNOLOGICAL PARAMETERS; INFANT; INJECTION SITE INDURATION; INJECTION SITE PAIN; MALAISE; MALE; MULTICENTER STUDY; MYALGIA; NORMAL HUMAN; PHASE 2 CLINICAL TRIAL; PRESCHOOL CHILD; PROTECTION; RANDOMIZED CONTROLLED TRIAL; SEROPROTECTION; SHIVERING; SOMNOLENCE; SWELLING; VACCINE SAFETY; VOMITING; BLOOD; CLINICAL TRIAL; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; GUATEMALA; IMMUNOLOGY; INFLUENZA, HUMAN; PATHOLOGY; PROCEDURES; VACCINATION;

ADJUVANTS, IMMUNOLOGIC; ANTIBODIES, VIRAL; CHILD, PRESCHOOL; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; GUATEMALA; HEMAGGLUTINATION INHIBITION TESTS; HUMANS; INFANT; INFLUENZA VACCINES; INFLUENZA, HUMAN; MALE; POLYSORBATES; SQUALENE; VACCINATION;

EID: 84907012975     PISSN: 20366590     EISSN: 19722680     Source Type: Journal    
DOI: 10.3855/jidc.4594     Document Type: Article

References (35)

1. Izurieta HS, Thompson WW, Kramarz P, Shay DK, Davis RL, DeStefano F, Black S, Shinefield H, Fukuda K (2000) Influenza and the rates of hospitalization for respiratory disease among infants and young children. N Engl J Med 342: 232-239.
2. Thompson WW, Shay DK, Weintraub E, Brammer L, Bridges CB, Cox NJ, Fukuda K (2004) Influenza-associated hospitalizations in the United States. JAMA 292: 1333-1340.
3. O'Brien MA, Uyeki TM, Shay DK, Thompson WW, Kleinman K, McAdam A, Yu XJ, Platt R, Lieu TA (2004) Incidence of outpatient visits and hospitalizations related to influenza in infants and young children. Pediatrics 113: 585-593.
4. Poehling KA, Edwards KM, Weinberg GA, Szilagyi P, Staat MA, Iwane MK, Bridges CB, Grijalva CG, Zhu Y, Bernstein DI, Herrera G, Erdman D, Hall CB, Seither R, Griffin MR; New Vaccine Surveillance Network (2006) The underrecognized burden of influenza in young children. N Engl J Med 355: 31-40.
5. Heikkinen T (2006) Influenza in children. Acta Paediatr 95: 778-784.
6. Marchisio P, Baggi E, Bianchini S, Principi N, Esposito S (2012) Clinical and socioeconomic impact of pediatric seasonal and pandemic influenza. Hum Vaccin Immunother 8: 17-20.
7. King JC Jr, Stoddard JJ, Gaglani MJ, Moore KA, Magder L, McClure E, Rubin JD, Englund JA, Neuzil K (2006) Effectiveness of school-based influenza vaccination. N Engl J Med 355: 2523-2532.
8. Reichert TA, Sugaya N, Fedson DS, Glezen WP, Simonsen L, Tashiro M (2001) The Japanese experience with vaccinating schoolchildren against influenza. N Engl J Med 344: 889-896.
9. Fiore AE, Uyeki TM, Broder K, Finelli L, Euler GL, Singleton JA, Iskander JK, Wortley PM, Shay DK, Bresee JS, Cox NJ (2010) Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2010. MMWR Recomm Rep 59: 1-62.
10. Principi N, Esposito S (2012) Adjuvanted influenza vaccines. Hum Vaccin Immunother 8: 59-66.
11. Jefferson T, Rivetti A, Harnden A, Di Pietrantonj C, Demicheli V (2008) Vaccines for preventing influenza in healthy children. Cochrane Database Syst Rev 2: CD004879.
12. Smith S, Demicheli V, Di Pietrantonj C, Harnden AR, Jefferson T, Matheson NJ, Rivetti A (2006) Vaccines for preventing influenza in healthy children. Cochrane Database Syst Rev 1: CD004879.
13. Englund JA, Walter EB, Fairchok MP, Monto AS, Neuzil KM (2005) A comparison of 2 influenza vaccine schedules in 6- to 23-month-old children. Pediatrics 115: 1039-1047.
14. Vesikari T, Pellegrini M, Karvonen A, Groth N, Borkowski A, O'Hagan DT, Podda A (2009) Enhanced immunogenicity of seasonal influenza vaccines in young children using MF59 adjuvant. Pediatr Infect Dis J 28: 563-571.
15. Block SL, Ruiz-Palacios GM, Guerrero ML, Beygo J, Sales V, Holmes SJ (2012) Dose-range study of MF59-adjuvanted versus nonadjuvanted monovalent A/H1N1 pandemic influenza vaccine in six- to less than thirty-six-month-old children. Pediatr Infect Dis J 31: e92-e98.
16. Banzhoff A, Gasparini R, Laghi-Pasini F, Staniscia T, Durando P, Montomoli E, Capecchi PL, di Giovanni P, Sticchi L, Gentile C, Hilbert A, Brauer V, Tilman S, Podda A (2009) MF59-adjuvanted H5N1 vaccine induces immunologic memory and heterotypic antibody responses in non-elderly and elderly adults. PloS one 4: e4384.
17. Fragapane E, Gasparini R, Schioppa F, Laghi-Pasini F, Montomoli E, Banzhoff A (2010) A heterologous MF59-adjuvanted H5N1 prepandemic influenza booster vaccine induces a robust, cross-reactive immune response in adults and the elderly. Clin Vaccine Immunol 17: 1817-1819.
18. Galli G, Hancock K, Hoschler K, DeVos J, Praus M, Bardelli M, Malzone C, Castellino F, Gentile C, McNally T, Del Giudice G, Banzhoff A, Brauer V, Montomoli E, Zambon M, Katz J, Nicholson K, Stephenson I (2009) Fast rise of broadly cross-reactive antibodies after boosting long-lived human memory B cells primed by an MF59 adjuvanted prepandemic vaccine. Proc Natl Acad Sci U S A 106: 7962-7967.
19. Khurana S, Chearwae W, Castellino F, Manischewitz J, King LR, Honorkiewicz A, Rock MT, Edwards KM, Del Giudice G, Rappuoli R, Golding H (2010) Vaccines with MF59 adjuvant expand the antibody repertoire to target protective sites of pandemic avian H5N1 influenza virus. Sci Transl Med 2: 15ra5.
20. Khurana S, Verma N, Yewdell JW, Hilbert AK, Castellino F, Lattanzi M, Del Giudice G, Rappuoli R, Golding H (2011) MF59 adjuvant enhances diversity and affinity of antibody-mediated immune response to pandemic influenza vaccines. Sci Transl Med 3: 85ra48.
21. Leroux-Roels I, Borkowski A, Vanwolleghem T, Dramé M, Clement F, Hons E, Devaster JM, Leroux-Roels G (2007) Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomised controlled trial. Lancet 370: 580-589.
22. Vesikari T, Forsten A, Borkowski A, Gaitatzis N, Banzhoff A, Clemens R (2012) Homologous and heterologous antibody responses to a one-year booster dose of an MF59(®) adjuvanted A/H5N1 pre-pandemic influenza vaccine in pediatric subjects. Hum Vaccin Immunother 8: 921-928.
23. Vesikari T, Forstén A, Herbinger KH, Cioppa GD, Beygo J, Borkowski A, Groth N, Bennati M, von Sonnenburg F (2012) Safety and immunogenicity of an MF59((R))-adjuvanted A/H5N1 pre-pandemic influenza vaccine in adults and the elderly. Vaccine 30: 1388-1396.
24. Banzhoff A, Haertel S, Praus M (2011) Passive surveillance of adverse events of an MF59-adjuvanted H1N1v vaccine during the pandemic mass vaccinations. Hum Vaccin 7: 539-548.
25. Black S, Della Cioppa G, Malfroot A, Nacci P, Nicolay U, Pellegrini M, Sokal E, Vertruyen A (2010) Safety of MF59-adjuvanted versus non-adjuvanted influenza vaccines in children and adolescents: an integrated analysis. Vaccine 28: 7331-7336.
26. Crucitti A, Tsai TF (2011) Explorations of clinical trials and pharmacovigilance databases of MF59®-adjuvanted influenza vaccines for associated cases of narcolepsy: a six-month update. Scand J Infect Dis 43: 11-12.
27. Tsai TF, Crucitti A, Nacci P, Nicolay U, Della Cioppa G, Ferguson J, Clemens R (2011) Explorations of clinical trials and pharmacovigilance databases of MF59(R)-adjuvanted influenza vaccines for associated cases of narcolepsy. Scand J Infect Dis 43: 702-706.
28. US Food and Drug Administration (2007) Guidance for industry: Clinical data needed to support the licensure of seasonal inactivated influenza vaccines. Maryland: USFDA. Available: http://www.fda.gov/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/Vaccines/ucm074794.htm. Accessed December 2013.
29. Palmer DF, Dowle WR, Coleman MT, Schild GC (1975) Advanced laboratory technicals for immunological diagnostics. U.S. Dept. Hlth. Ed. Welfare, P.H.S. Atlanta, Immunology ser. Nr. 6 Part 2 haemagglutination-inhibition test. 1975: 25-62
30. Vesikari T, Knuf M, Wutzler P, Karvonen A, Kieninger-Baum D, Schmitt HJ, Baehner F, Borkowski A, Tsai TF, Clemens R (2011) Oil-in-water emulsion adjuvant with influenza vaccine in young children. N Engl J Med 365: 1406-1416.
31. Vesikari T, Groth N, Karvonen A, Borkowski A, Pellegrini M (2009) MF59-adjuvanted influenza vaccine (FLUAD) in children: safety and immunogenicity following a second year seasonal vaccination. Vaccine 27: 6291-6295.
32. Reyes L, Arvelo W, Estevez A, Gray J, Moir JC, Gordillo B, Frenkel G, Ardón F, Moscoso F, Olsen SJ, Fry AM, Lindstrom S, Lindblade KA (2010) Population-based surveillance for 2009 pandemic influenza A (H1N1) virus in Guatemala, 2009. Influenza Other Respi Viruses 4: 129-140.
33. Finkelman BS, Viboud C, Koelle K, Ferrari MJ, Bharti N, Grenfell BT (2007) Global patterns in seasonal activity of influenza A/H3N2, A/H1N1, and B from 1997 to 2005: viral coexistence and latitudinal gradients. PloS one 2: e1296.
34. Silvennoinen H, Peltola V, Vainionpaa R, Ruuskanen O, Heikkinen T (2011) Incidence of influenza-related hospitalizations in different age groups of children in Finland: a 16-year study. Pediatr Infect Dis J 30: e24-e28.
35. US Centers for Disease Control and Prevention (2011) Seasonal influenza activity surveillance reports:1997-1998 to 2009-2010 seasons. Atlanta: CDC. Available: http://www.cdc.gov/flu/weekly/fluactivitysurv.htm. Accessed December 2013.